Курсовая работа: Применение радиоактивного йода при лечении дифференцированного рака щитовидной железы
Ceccarelli C., Bencivelli W., Morciano D., et al. 131I therapy for
differentiated thyroid cancer leads to an earlier onset of menopause: results
of a retrospective study. // J Clin Endocrinol Metab; 2001 86(8):3512-5
Chebotareva E.D., Dzhuzha D.A., Shishkina V.V., et al. Treatment
and monitoring of patients with differentiated cancer of thyroid gland. // Klin
Khir; 2000 (11):39-41
Cholewinski S.P., Yoo K.S., Klieger P.S., O'Mara R.E. Absence of
thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. // J
Nucl Med; 2000 41(7):1198-202
Chopra S., Wastie M.L., Chan S., et al. Assessment of completeness
of thyroid ablation by astimation of neck uptake of 131-I on whole-body scans:
Comparison of quantification and visual assessment of thyroid bed uptake. //
Nucl Med Commun; 1996 17: 687-91
Clark T., Becker S.V., Becker D.V. Radioiodine and clinical
medicine: an historical perspectave. // International symposium on radioiodine.
USA Rochester 1996. Program and Abstracts p.33
Connon C.S., Thomas J.H., Robinson R.G., et al. Radioiodine
therapy for differentiated thyriod carcinoma. // Am J Surg; 1988 156(6):519-21
David A., Blotta A., Bondanelli M., et al. Serum thyroglobulin
concentrations and (131)I whole-body scan results in patients with
differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating
hormone. // J Nucl Med; 2001 42(10):1470-5
de Keizer B., Koppeschaar H.P., Zelissen P.M., et al. Efficacy of
high therapeutic doses of iodine-131 in patients with differentiated thyroid
cancer and detectable serum thyroglobulin. // Eur J Nucl Med; 2001
28(2):198-202
De Klerk J.M.H., De Keizer B., Zelissen P.M.J., Lips C.M.J.,
Korreschaar H.P.F. Fixed dosage of 131I for remnant ablation in patients with
differentiated thyroid carcinoma without pre-ablative diagnostic 131I
scintigrafy. // Nucl Med Comm; 2000 21: 529-532
Delisle M.J., Schvartz C. 131 iodine and differentiated thyroid
cancers. // Ann Endocrinol (Paris); 1996 57(3):186-93
Dietlein M., Moka D., Scheidhauer K., et al. Follow-up of
differentiated thyroid cancer: comparison of multiple diagnostic tests. // Nucl
Med Commun; 2000 21(11):991-1000
Dottorini M.E., Vignati A., Mazzucchelli L., et al. Differentiated
thyroid carcinoma in children and adolescents: a 37-year experience in 85
patients. // J Nucl Med; 1997 38(5):669-75
Driedger A.A., Kidane H.G., Pewe J.E. Impact of I-131 uptake on
ablation of post surgical remnants.// International symposium on radioiodine.
USA Rochester 1996. Program and Abstracts p.68
Falesi M., Signore A., Ventroni G., et al. Role initial iodine-131
whole-body scan and serum thyroglobulin in differentiated thyriod carcinoma
metastases. // J Nucl Med; 1998 39(9):1542-6
Farahari J., Parlowsky T., Mader U., et al. Differentiated thyroid
cancer in children and adolescents. // Langenbecks Arch Surg; 1998 383(3):235 —
239.
Farina G.P., Pisano M., Baccoli A., et al. Therapeutic strategies
in differentiated cancer of the thyroid: total thyroidectomy. // G Chir; 2000
21(11-12):469-74
Goslings B.M., Pelikan H.L., Lion J. Resalts of I-131 treatment in
advanced stages of differentiated thyroid carcinoma (DTC). // International
symposium on radioiodine. USA Rochester 1996. Program and Abstracts p.61
Grant C.S. Operattive and postoperative manegement of the patient
with follicular and Hurthler cell carcinoma: Do they differ- // Surg. Clin.
North Am. –1995.-Vol.75,№3. – P.395-403.
Grigsby P. Cost minimization analysis and utility of pretreatment
and posttreatment total body ioidine-131 scans in patients with thyriod
carcinoma. // Cancer; 1998 82(5):931-5
Grunwald F., Menzel C., Bender H., et al. Redifferentation therapy
— induced radioiodine uptake in thyriod cancer. // J Nucl Med; 1998
39(11):1903-6
Gulzar Z., Jana S., Young I., et al. Neck and whole-body scanning
with 5-mCi dose of (123)I as diagnostic tracer in patients with
well-differentiated thyroid cancer. // Endocr Pract; 2001 7(4):244-9
Haigh P.I., Ituarte P.H., Wu H.S., et al. Completely resected
anaplastic thyroid carcinoma combined with adjuvant chemotherapy and
irradiation is associated with prolonged survival. // Cancer; 2001
91(12):2335-42
Hall P., Mattsson A., Boice J.D. Thyroid cancer after diagnostic
administration of iodine-131. // Radiat Res; 1996 145(1):86 — 92.
Hermanska J., Karny M., Zimak J., et al. Improved prediction of
therapeutic absorbed doses of radioiodine in the treatment of thyroid
carcinoma. // J Nucl Med; 2001 42(7):1084-90
Hodgson D.C., Brierley J.D., Tsang R.W., Panzarella T. Prescribing
131Iodine based on neck uptake produces effective thyriod ablation and reduced
hospital stay. // Radiother Oncol; 1998 47(3):325-30
Hurley J.R. Management of thyroid cancer: radioiodine ablation,
"stunning," and treatment of thyroglobulin-positive, (131)I
scan-negative patients. // Endocr Pract; 2000 6(5):401-6
Ikekubo K. Hino M., Ito H., et al. The early detection of
metastases differentiated thyriod cancer using 131-I total body scan and
treatment with 131I. // Kaku Igaku; 1991 28(3):247-59
Jochansen K, Woodhoyse N.J., Odugbesan O. Comparison of 1073 and
3700 MBq MBq iodini-131 in postoperative ablation of residual thyriod tissue in
patients with differentiated thyriod cancer. // J Nucl Med; 1991 32(2):352-4
Kao C.H, Yen T,C. Stunning effects after a diagnostic dose of
iodine-131. // Nuklearmedizin; 1998 37(1):30-2
Kasagi K., Miyamoto S., Endo K., et al. Increased uptake of
ioidine-131 in metastases od differentiated thyriod carcinoma associated with
less severe hypothyroidism following total thyroidectomy. // Cancer; 1993
72(6):1983-90
Khan J.H., McElhinney D.B., Rahman S,B., et al. Pulmonary
metastases of endocrine origin: the role of surgery. // Chest; 1998
114(2):526-34
Kim J.H., Kim E.S., Lee J.V. Radiation dosimetry of in vivo and in
vitro irradiation of iodine-131. // International symposium on radioiodine. USA
Rochester 1996. Program and Abstracts p.82
Kitazono M., Robey R., Zhan Z., et al. Low concentrations of the
histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of
the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated
thyroid carcinoma cells. // J Clin Endocrinol Metab; 2001 86(7):3430-5
Koerber C., Schmutzler C., Rendl J., et al. Increased I-131 uptake
in local recurrence and distant metastases after second treatment with retinoic
acid. // Clin Nucl Med 1999 24(11):849-851
Koong S.S., Reynjlds J.C., Movius E.D., et al. Lithyum as a
potentional adjuvant to 131I therapy of metastatic well differentiated thyriod
carcinoma. // J Clin Endocrinol Met; 1999 84(3):912-6
Krausz Y. Nuclear endocrinology as a monitoring tool. // Semin
Nucl Med; 2001 31(3):238-50
Krishnamurthy G.T., Blahd W.H. Radioiodine I-131 therapy in the
management of thyriod cance. A prospective study. // Cancer; 1977 40(1):195-202
Kuriakose M.A., Hicks W.L., Loree T.R., et al. Risk group-based
management of differentiated thyroid carcinoma. // J R Coll Surg Edinb; 2001
46(4):216-23
Ladenson P.W., Ewertz M.E., Dickey R.A. Practical application of
recombinant thyrotropin testing in clinical practice. // Endocr Pract; 2001
7(3):195-201
Leger A.F. Distant metastasis of differentiated thyroid cancers.
Diagnosis by 131 iodine (I 131) and treatment. // Ann Endocrinol (Paris); 1995
56(3):205-8
Leger F.A., Izembart M., Dagousset F., et al. Decreased uptake of
therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for
thyriod remnants in differentiated thyriod carcinoma. // Eur J Nucl Med 1998
25(3):242-6
Lerch H., Schober O., Kuwert T., Saur H.B. Survival of
differentiated thyriod carcinoma studiedin 500 patients. // J Clin Oncol; 1997
15(5):2067-75
Leung S.F., Law M.W., Ho S.K. Efficacy of low-dose iodine-131
ablation of post-operative thyriod remnants: a study of 69 cases. // Br J
Radiol 1992 65(778):905-9
Lin J.D., Chao T.C., Huang M.J., et al. Use of radioactive iodine
for thyriod remnant ablation in well-differentiated thyriod carcinoma to
replace thyriod reoperation. // Am J Clin Oncol; 1998 21(1):77-81
Lin J.D., Kao P.F., Chao T.C. The effect of radioactive iodine in
thyriod remnant ablation and treatment of well differentiated thyriod
carcinoma. // Br J Radiol; 1998 71(843):307-13
Lin W.Y., Shen Y.Y., Wang S.J. Short-term hazards of low-dose
radioiodine ablation therapy in postsurgical thyroid cancer patients. // Clin
Nucl Med, 1996 21(10):780-2
Lind P. 131I whole body scintigraphy in thyriod cancer patients.
// Q J Nucl Med; 1999 43(3):188-94
Lippi F., Capezzone M., Angelini F., et al. Radioiodine treatment
of metastatic differentiated thyroid cancer in patients on L-thyroxine, using
recombinant human TSH. // Eur J Endocrinol; 2001 144(1):5-11
Logue J.P.,Tsang R.W., Brierley J.D., Simpson W.J. Radioiodine
ablation of residual tissue in thyriod cancer: relationship between
administered activity, neck uptake and outcome. // Br J Radiol; 1994
67(803):1127-31
Makarewicz L., Mikosinski S, Karwowoska A. at al. Comparision of
test and therapeutic activity kinetics of 131J. // International symposium on
radioiodine. USA Rochester 1996. Program and Abstracts p.63
Mandel S.J., Shankar L.K., Benard F., et al. Superiority of
iodine-123 compared with iodine-131 scanning for thyroid remnants in patients
with differentiated thyroid cancer. // Clin Nucl Med; 2001 26(1):6-9
Matsushita T., Toyota S., Katoh N., Nakagawa T. Iodine-131
treatment of thyriod cance: relation between effective half-life and efficacy
of treatment. // Radiat Med; 1994 12(4):167-70
Maxon H.P., Thomas S.R., Hertzberg V.S., et al. Relation between
effective radiation dose and outcome of radioiodine therapy for thyriod cancer.
// New Eng J Med; 1983 309:937
Maxon H.R. The role of radioiodine in the treatment of childhood
thyroid cancer – A dosimetric approach. // In: NIH proceedings of a workshop,
September 10-11, 1992, p. 109-116.
Mazzaferri E.L. Thyroid remnant ablation in the treatment of
differentiated thyroid carcinoma. // International symposium on radioiodine.
USA Rochester 1996. Program and Abstracts p.77
Mazzaferri E.L., Young R.L. Papillary thyroid carcinoma: A 10-year
follow-up report of the impact of therapy in 576 patients. // Am J Med; 1981
70(3):511-18.
McDougall I.R. 131I treatment of 131I negative whole-body scan,
and positive thyroglobulin in differentiated thyriod carcinoma: what is being
treated? // Thyriod; 1997 7(4):669-72
McDougall I.R. Whole-body scintigraphy with radioiodine-131. A
comprehensive list of false-positives with some examples. // Clin Nucl Med;
1995 20(10):869-75
Melliere D., Berrahal D., Hindie E., et al. Surveillance after
treatment of differentiated thyroid cancers. // Ann Chir; 2000 125(9):856-60
Menzel C., Grunwald F., Schomburg A., et al. "High-dose"
radioiodine therapy in advanced differentiated thyroid carcinoma. // J Nucl
Med; 1996 37(9):1496-503
Miyamoto S., Kasagi K., Endo K., et al. Resalts of radioiodine
therapy in 47 patients with distant metastases of differentiated thyriod
carcinoma. // Nippon Igaku Hoshasen Gakkai Zasshi; 1991 51(7):810-21
M'Kacher R., Schlumberger M., Lregal J.D, et al. Biologic
dosimetry in thyroid cancer patients after repeated treatments with iodine-131.
// J Nucl Med; 1998 39(5):825-9
Morris L.F., Waxman A.D., Braunstein G.D. The nonimpact of thyroid
stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. //
J Clin Endocrinol Metab; 2001 86(8):3507-11
Muratet J.P. Giraud P., Daver А.,
et al. Predicting the efficacy of first iodine-131 treatment in differentiated
thyriod carcinoma. // J Nucl Med; 1997 38(9):1362-8
Muratet J.P., Daver А.,
Minier J.F., Larra F. Influence of scanning dose of iodine-131 on subsequent
first ablative treatment outcome in patients operated on for differentiated
thyriod carcinoma. // J Nucl Med 1998; 39(9):1546-50
North D.L., Shearer D.R., Hennessey J.V., Donovan G.L. Effective
half-life of 131I in thyroid cancer patients. // Health Phys; 2001 81(3):325-9
O`Connel M.E., Flover M,A,, Hinton P,J., et al. Radiation dose
assessment in radioiodine therapy. Dose-response relationships in
differentiated thyriod carcinoma using quantitive scanning and PET. //
Radiother Oncol; 1993 28(1):16-26
O`Doherty M.J., Coakley A.J. Drug therapy alternatives in the
treatment of thyriod cancer. // Drugs; 1998 55(6):801-12
Ozaki O., Ito K., Manabe Y., et al. Clinical study on pulmonary
metastases of differentiated thyriod carcinoma — with special reference to the
extent of thyriod resection and RI therapy. // Nippon Geka Gakkai Zasshi; 1985
86(12):1596-9
Paloyan E., Walker R.P., Lawrence A.M. Guidelines for the use of
radioiodine, thyriod hormone, and treatment of metastatic disease in patients
with differentiated thyriod cancer. // Surg Oncol Clin N Am; 1998 7(4):665-80
Paryani S.B., Chobe R.J., Scott W., et al. Manegement of thyroid
carcinoma with radioactive 131I. // J Radiat Oncol Biol Phys; 1996 36(1):83-6
Pelican D.M., Lion H.L., Hermans J., Goslings B.M. The role of
radioactive iodine in the treatment of advanced differentiated thyriod
carcinoma. // Clin Endocrinol (Oxf); 1997 47(6):713-20
Petrich T., Borner A.R., Weckesser E., et al. Follow-up of
differentiated thyroid cancer patients using rhTSH — preliminary results. //
Nuklearmedizin; 2001 40(1):7-14
Pichon M.F., Basuyau J.P., Gory-Delabaere G., et al. Standards,
options and recommendations for blood tumor markers in thyroid cancers. // Bull
Cancer; 2001 88(8):775-92
Pineda J.D., Lee T., Ain K., et al. Iodine-131 therapy for thyroid
cancer patients with elevated thyroglobulin and negative diagnostic scan [see
comments]. // J Clin Endocrinol Metab; 1995 80(5):1488-92
Ramanna L., Waxman A.D., Brachman M.B., et al. Evaluation of
low-dose radioiodine ablation therapy in postsurgical thyriod cancer patients.
// Clin Nuck Med; 1985 10(11):791-5
Reynolds J.C. How much uptake is enough to treat? Are post therapy
scans worhwhile? // International symposium on radioiodine. USA Rochester 1996.
Program and Abstracts p.81
Reynolds J.C., Comparison of I-131 absorbed radiation doses in
children and adalts: a tool for estimating therapeutic I-131 doses in children.
// In: NIH proceedings of a workshop, September 10-11, 1992, p. 125-133.
Reynolds J.C., Robbins J. The changing role of radioiodine in the
management of differentiated thyriod cancer. // Semin Nucl Med; 1997
27(2):152-64
Ronga G., Fiorentino A., Paserio E., et al. Can iodine-131
whole-body scan be replaced by thyroglobulin measurement in post-surgical
follow-up of differentiated thyriod carcinoma. // J Nucl Med; 1990
31(11):1766-71
Rosler H., Birrer A., Luscher D., Kinser J. Long-term course in
differentiated thyroid gland carcinoma. // Schweiz Med Wochenschr; 1992
122(48):1843-57
Salvatori M., Rufini V., Garganese M.C., Di Giuda D. Radioiodine
therapy in differentiated thyroid carcinoma. // Rays; 2000 25(2):221-38
Samaan N.A., Schultz P.N., Haynie T.P., Ordonez N.G. Pulmonary
metastases of differentiated thyriod carcinoma: treatment results in 101
patients. // J Clin Endocrinol Metab; 1985 60(2):376-80
Samaan, N.A., Schultz P.N. Hickey R.C. et al. The result of
various modalities of treatment of well differentiated thyroid carcinoma: a
retrospective rewiew of 1599 patients. // J Clin Endocrin Metabol; 1992
75(3):714-720
Samuel A.M., Rajashekharrao B., Shah D.H. Pulmonary metastases in
children and adolescents with well-differentiated thyriod cancer. // J Nucl
Med; 1998 39(9):1531-6
Sanders L.E., Cady B. Differentiated thyroid cancer: Reexamination
of risk groups and outcome of treatment. // Arch. Surg. –
1998.-Vol.133.№4.-P.419-425.
Santora J., Nemec J., Kubinyi J. Therapy of thyroid carcinoma
using radioiodine. // Cas Lek Cesk; 2001 140(7):217-9
Sarkar S.D., Afriyie M.O., Palestro C.J. Recombinant human
thyroid-stimulating hormone-aided scintigraphy: comparison of imaging at
multiple times after I-131 administration. // Clin Nucl Med; 2001 26(5):392-5
Schicha H., Dietlein M. Radioiodine therapy in differetiated
thyroid gland carcinoma. Zentralbl Chir; 1997 122(4):266-73
Schlumberger M. I 131 therapy for elevated thyroglobulin levels.
// International symposium on radioiodine. USA Rochester 1996. Program and
Abstracts p.77
Schlumberger M., Challeton C., De Vathaire F., et al. Radioactive
Iodine Treatment and External Radiotherapy for Lung and Bone Metastases from
Thyroid Carcinoma. // J Nucl Med; 1996 37(4):598-605
Schlumberger M., Pacini F. Thyroid tumors. // Editions Nucleon,
Paris, 1999 317pp.
Schlumberger M.J., Torlantano M. Papillary and follicular thyroid
carcinoma. // Baillieres Best Pract Res Clin Endocrinol Metab; 2000
14(4):601-13
Schmutzler C. Regulation of the sodium/iodide symporter by
retinoids--a review.review. Exp Clin Endocrinol Diabetes. 2001;109(1):41-4.
Review.
Shyh-Ing Guan, Wei-Jen Chang, Ming-Yang Yeh, Wei-Lian Chen. The
effect of I-131 radionuclide therapy for carcinoma of thyroid on natural killer
cell activity. // International symposium on radioiodine. USA Rochester 1996.
Program and Abstracts p.79
Siddiqi A., Foley R.R., Britton K.E., et al. The role of
123I-diagnostic imaging in the follow-up of patients with differentiated
thyroid carcinoma as compared to 131I-scanning: avoidance of negative
therapeutic uptake due to stunning. // Clin Endocrinol (Oxf); 2001 55(4):515-21
Simon D., Koehrle J, Reiners C., et al. Redifferentation therapy
with retinoids: therapeutic option for advanced follicular and papillary
thyriod carcinoma. // World Surg; 1998 22(6):569-74
Sisson J., Jamader D., Kazerooni T. at al. 131-I treatment of
micronodular lung metastases from papillary thyroid cancer: are the tumor too
small? // International symposium on radioiodine. USA Rochester 1996. Program
and Abstracts p.82
Sisson J.C., Giordano T.J., Jamadar D.A., et al. 131-I treatment
of micronodular pulmonary metastases from papillary thyroid carcinoma. //
Cancer; 1996 78(10):2184-92
Smanik P.A., Cho J-C, Jhiang S.M. Cloning of human sodium/iodine
transportet and mechanism of the loss radioiodine uptake activity in thyroid
tumors.// International symposium on radioiodine. USA Rochester 1996. Program
and Abstracts p.80
Solans R., Bosch J.A., Galofre P., et al. Salivary and lacrimal
gland dysfunction (sicca syndrome) after radioiodine therapy. // J Nucl Med;
2001 42(5):738-43
Sykes A.J., Gattamaneni H.R. Carcinoma of the thyriod in children:
a 25-year experience. // Med Pediatr Oncol; 1997 29(2):103-7
Tatar F.A., Morita E., Ituarte P.H., et al. Association between
residual thyroid carcinoma and diffuse hepatic uptake of 131I following
radioiodine ablation in postoperative total thyroidectomy patients. // World J
Surg; 2001 25(6):718-22
Travagli J.P., Cailleux A.F., Ricard M, et al. Combination of
radioiodine (I-131) and probe-guided surgery for persistent or recurrent
thyroid carcinoma. // J Clinl Endocrinol Metab; 1998 83(8):2675-80
Tsahg R.W., Brierley J.D., Simpson W.J., et al. The effects of
surgery, radioiodine, and external radiation therapy on the clinical outcome of
patients with differentiated thyriod carcinoma. // Cancer; 1998 82(2):375-88
van Wyngaarden M., McDougall I.R. What the role of 1100 MBq
(<30mCi) radioiodine 131I in the treatment of patients with differentiated
thyriod cancer? // Nucl Med Commun; 1996 17(3):199-207
Vermiglio F., Violi M.A., Finocchiaro M.D., et al. Short-term
effectiveness of low-dose radioiodine ablative treatment of thyriod remnants
after thyroidectomy for differentiated thyriod cancer. // Thyriod; 1999
9(4):387-91
Wong J.B., Kaplan M.M., Meyer K.B., Pauken S.G. Ablative
radioactive iodine therapy for apparently localized thyriod carcinoma. A
dicision analitic perspective. // Endocrinol Metab Clin North Am; 1990
19(3):741-60
Zanzonico P.B. Radioiodine dose to patients and relatives incident
to I131 therapy. // International symposium on radioiodine. USA Rochester 1996.
Program and Abstracts p.35
Zimmerman D., Hay I., Bergstralh T. Papillary thyroid cancer in
childhood. // In: NIH proceedings of a workshop, September 10-11, 1992, p. 3 —
10.
Zohar Y., Strauss M. Occult distant metastases of
well-differentiated thyriod carcinoma. // Head Neck; 1994 16(5):438-42
|